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A critical unresolved issue about the genotoxic
stress response is how the resulting activation
of the p53 tumor suppressor can lead either to
cell-cycle arrest and DNA repair or to apopto-
sis. We show here that hematopoietic zinc fin-
ger (Hzf), a zinc-finger-containing p53 target
gene, modulates p53 transactivation functions
in an autoregulatory feedback loop. Hzf is in-
duced by p53 and binds to its DNA-binding do-
main, resulting in preferential transactivation of
proarrest p53 target genes over its proapop-
totic target genes. Thus, p53 activation results
in cell-cycle arrest in Hzf wild-type MEFs, while
inHzf/MEFs, apoptosis is induced. Exposure
of Hzf null mice to ionizing radiation resulted in
enhanced apoptosis in several organs, as com-
pared to in wild-type mice. These findings pro-
vide novel insights into the regulation of p53
transactivation function and suggest that Hzf
functions as a key player in regulating cell fate
decisions in response to genotoxic stress.
INTRODUCTION
p53 is an important component of pathways mediating
cellular response to genotoxic stress by inducing the tran-
scription of a variety of genes that regulate diverse cellular
processes including cell-cycle progression, apoptosis,
and genomic stability (Harris and Levine, 2005; Vogelstein
et al., 2000; Vousden and Lu, 2002). However, little is
known about the mechanism (or mechanisms) that deter-
mines which sets of target genes—i.e., cell-cycle arrest
genes like p21 (El-Deiry et al., 1993) and 14-3-3s (Her-
meking et al., 1997) or proapoptotic genes such as Bax
(Miyashita and Reed, 1995), Noxa (Oda et al., 2000; Vil-
lunger et al., 2003), Pidd (Lin et al., 2000), Puma (Nakano
and Vousden, 2001; Villunger et al., 2003), Perp (Attardi624 Cell 130, 624–637, August 24, 2007 ª2007 Elsevier Inc.et al., 2000), etc.—are transactivated by p53 under a spe-
cific condition. In order to perform its cellular functions,
p53 must rapidly accumulate in response to stressful con-
ditions, as its basal level is very low. Activation of p53 has
two major outcomes: cell-cycle arrest or apoptosis. Cell-
cycle arrest allows DNA repair to take place before repli-
cation occurs, thereby maintaining genomic integrity. On
the other hand, apoptosis results in elimination of irrepara-
bly damaged cells.
The regulation of p53 is usually achieved by posttrans-
lational modifications and through its interactions with
various other proteins (Lavin and Gueven, 2006). p53 un-
dergoes phosphorylations on numerous serine residues
in both N-and C-terminal regions (Lavin and Gueven,
2006). The N-terminal phosphorylations inhibit its interac-
tions with its negative regulator Mdm2 (Canman et al.,
1998; Chehab et al., 2000; Khosravi et al., 1999), while
the C-terminal phosphorylations are thought to enhance
its sequence-specific DNA-binding ability by inducing
a conformational change (Hupp et al., 1992; Wang and
Prives, 1995). Similarly, other modifications like ubiquiti-
nation, acetylation, and sumoylation also affect its proteo-
lytic turnover and sequence-specific DNA-binding ability
(Brooks and Gu, 2006; Rodriguez et al., 1999). This can
also be achieved by its interaction with cellular proteins
such as Pin-1, ASPP family members, etc. (Braithwaite
et al., 2006). When Pin-1 binds to p53, it undergoes a con-
formational change that enhances its transactivation abil-
ity (Zacchi et al., 2002; Zheng et al., 2002). Recently, the
ASPPs have been found to be potent activators of p53,
providing an important insight into how p53 responds to
apoptotic signals (Trigiante and Lu, 2006). The ASPP fam-
ily consists of three members: ASPP1, ASPP2, and iASPP.
ASPP1 and ASPP2 interact with p53 and specifically en-
hance p53-induced apoptosis but not cell-cycle arrest,
while iASPP binds p53 and inhibits p53-mediated apopto-
sis (Bergamaschi et al., 2006; Samuels-Lev et al., 2001).
While studying the genome-wide transcriptional re-
sponse to p53 induction, we found that one of the genes
upregulated was the hematopoietic zinc finger (Hzf)
gene. Hzf was originally identified as a gene induced in
hematopoietic progenitor cells following differentiation of
murine embryonic stem cells (Hidaka et al., 2000). Hzf en-
codes a zinc-finger protein of 366 amino acids with three
C2H2-type zinc-finger domains. The zinc-finger domains
in Hzf are widely spaced with long linker regions connect-
ing the fingers, as a consequence of which it cannot form
any stable nucleic acid-protein complexes (Sharma et al.,
2004). Recently, it was reported that Hzf is a direct tran-
scriptional target of p53 that plays a role in p53-mediated
cell-cycle arrest in response to DNA damage in NIH 3T3
cells (Sugimoto et al., 2006). We found that Hzf is unique
among the different p53 transcriptional targets in that,
upon induction by p53 or DNA damage, it binds to the
p53 DNA-binding domain and modulates its transactiva-
tion function in an autoregulatory feedback loop. We fur-
ther investigated the role of Hzf in the p53-mediated
DNA damage response. Here, we show that when Hzf
binds to p53, it is preferentially recruited to the promoters
of its pro-cell-cycle-arrest target genes rather than to its
proapoptotic target genes. Thus, in the presence of Hzf,
p53-mediated cell-cycle arrest is promoted while apopto-
sis is repressed in response to genotoxic stress.
RESULTS
Inhibition of Hzf Induction in Response to DNA
Damage Represses p21 Expression but Enhances
Bax Levels
Through microarray analysis of cDNA expression, we pre-
viously identified Hzf as one of the upregulated genes
whose transcript levels are elevated in response to p53
induction (Han et al., 2002). To confirm the array result,
we carried out several northern and western blot analyses
to examine Hzf expression in response to different types
of stresses in several cell lines of diverse tissue origin
and different p53 background. Under various stress con-
ditions including DNA damage and oxidative stress, Hzf
was induced in a p53-dependent manner (Figure 1A).
Moreover, promoter analysis including the reporter gene
assay and chromatin immunoprecipitation (ChIP) analysis
supported the conclusion that Hzf is a direct p53 tran-
scriptional target (see Figure S1 in the Supplemental
Data available with this article online).
To investigate the role of Hzf in p53-mediated stress
response, we examined whether Hzf induction contributes
directly to the ability of p53 to transactivate p21 and Bax.
To do so, we used short hairpin RNA (shRNA) against Hzf
to knock down the induction of endogenous Hzf in re-
sponse to p53-dependent DNA damage response or ec-
topic p53 expression. We transiently transfected U2OS
(wild-type [WT] p53) and EJ (nonfunctional p53) cell lines
with Hzf shRNA or scrambled shRNA constructs followed
by treatment with the chemotherapeutic agent etoposide
or infection with Ad-p53 to induce p53 expression
(Figure 1B). Transfection of Hzf shRNA resulted in the
suppression of endogenous Hzf induction by etoposide
treatment or Ad-p53 infection, while control scrambled
shRNA had no effect on induced Hzf levels. In U2OS cellstransfected with the scrambled shRNA construct, upon
etoposide treatment or Ad-p53 infection, concomitant
with p53 induction, Hzf and p21 induction was seen while
Bax levels were minimally increased. However, depletion
of Hzf expression resulted in enhanced Bax induction
while p21 induction was significantly reduced in response
to DNA damage (Figure 1B, left panel). In EJ cells contain-
ing nonfunctional p53, similar results were obtained with
Ad-p53 infection (Figure 1B, right panel). To exclude off-
target effects of shRNA, two other Hzf shRNAs were
used, and similar results were obtained (data not shown).
We next examined the levels of p21 and Bax transcripts
in response to DNA damage (via etoposide treatment) in
Hzf+/+ and Hzf/ MEFs. As shown in Figure 1C, Hzf/
MEFs showed drastically lower induction levels of p21
mRNA than Hzf+/+ MEFs, while Bax induction was signifi-
cantly enhanced inHzf/ MEFs. To further investigate the
role of Hzf in p53-mediated transcription of these target
genes, we used reporter assays with either the p21 or
Bax promoter fused to a luciferase reporter (pGL3-basic,
pGL3-p21-Luc, and pGL3-Bax-Luc). U2OS and EJ cells
were cotransfected with Hzf shRNA or scrambled shRNA
constructs together with pGL3-basic, pGL3-p21-Luc, or
pGL3-Bax-Luc constructs followed by treatment with eto-
poside or infection with Ad-p53 (Figure 1D). We found that
the ability of p53 to transactivate the p21 promoter was
severely compromised upon knockdown of Hzf, while its
ability to transactivate the Bax promoter was significantly
enhanced in response to etoposide treatment or Ad-p53
infection in U2OS cells containing WT p53 (Figure 1D, up-
per panel). In the EJ cells, this effect was also observed
upon ectopic p53 expression (Figure 1D, lower panel).
All of these results suggested that Hzf affects p53-medi-
ated transcription in a positive manner for p21 transcrip-
tion and in a negative manner for Bax transcription.
Hzf Is Induced by p53 and Binds Directly to Its
DNA-Binding Domain
Because Hzf is a zinc-finger protein (Hidaka et al., 2000)
that is induced by p53 and modulates p53-mediated
transactivation, we next tested whether Hzf physically in-
teracts with p53. For this purpose, we utilized extracts
made from U2OS cells treated with etoposide or EJ cells
infected with Ad-p53 for immunoprecipitation using the
p53-specific monoclonal antibody PAb1801. In both cell
lines, we found that Hzf coimmunoprecipitated with p53
(Figure 2A, top panels). We also performed a reverse
coimmunoprecipitation experiment in which immunopre-
cipitation was carried out using anti-Hzf polyclonal anti-
body. As shown in Figure 2A (bottom panels), p53 also
coimmunoprecipitated with Hzf. As a control, an immuno-
precipitation was carried out in etoposide-treated Hzf/
MEFs using Hzf antibody. As shown in Figure S2, p53
did not appear in the precipitated complex, and no Hzf
was detected, confirming the specificity of the Hzf anti-
body used.
To determine whether the interaction between Hzf
and p53 is a direct one, a yeast two-hybrid assay wasCell 130, 624–637, August 24, 2007 ª2007 Elsevier Inc. 625
Figure 1. Hzf Induction in Response to Various Stresses Modulates p53 Transcriptional Function
(A) Hzf is induced by genotoxic and oxidative stress in a p53-dependent manner. HCT116, HCT116 p53/, U2OS, and LNCaP cells were treated with
etoposide (ETO, 40 mM), ionizing radiation (IR) (4 Gy), or H2O2 (0.4 mM) for the indicated periods. The cells were then harvested, and northern blots or
western blots were performed.
(B) Loss of Hzf represses p21 induction but enhances Bax expression in response to DNA damage or ectopic p53. U2OS and EJ cells were treated
with etoposide (ETO, 40 mM) or infected with Ad-p53, respectively, for 24 hr. The cells were then harvested, and western blots were performed for the
indicated proteins.
(C) Wild-type and Hzf/ MEFs were treated with etoposide (ETO, 40 mM) for 24 hr. The cells were then harvested, and northern blots were performed
as indicated.
(D) Effects of Hzf inhibition on p53-mediated transcription. Reporter gene constructs containing p53-responsive elements (pGL3-p21-Luc or pGL3-
Bax-Luc) or control vector alone (pGL3-Basic) were cotransfected into U2OS and Saos2 cells with either Hzf shRNA or control scrambled shRNA, and
24 hr later, cells were treated with etoposide or infected with Ad-p53 for another 24 hr. At the end of this period, luciferase assay was performed. Error
bars are means ± SD of three independent experiments with duplicate samples.performed. Expression constructs in which p53 was fused
to the Gal4 DNA-binding domain (pGBKT7-p53) and Hzf
was fused to the Gal4 transactivation domain (pGADT7-
Hzf) were generated and then transformed into yeast
strains AH109 and Y187, respectively. Blue-colored
Ade+/His+ colonies were obtained when yeast transform-
ants containing pGBKT7-p53 and pGADT7-Hzf were626 Cell 130, 624–637, August 24, 2007 ª2007 Elsevier Inc.mated, as observed in a positive control mating experi-
ment between p53 (pGBKT7-p53) and SV40 T antigen
(pGADT7-T Ag) (Figure 2B) (Iwabuchi et al., 1993; Li and
Fields, 1993).
To map the domain of p53 to which Hzf binds, we car-
ried out GST pull-down experiments in which constructs
expressing different domains of p53 fused to GST were
Figure 2. Hzf Physically Interacts with p53
(A) U2OS and EJ cells were treated with ETO (40 mM) or infected with Ad-p53, respectively, for 24 hr. The cells were then harvested and subjected to
immunoprecipitations using anti-p53 antibody (top panels) or anti-Hzf antibody (bottom panels), and western blots were performed for the indicated
proteins.
(B) Yeast two-hybrid assay to show direct interaction between Hzf and p53 was carried out as described in Experimental Procedures.
(C) The region of p53 involved in binding to Hzf was analyzed in GST pull-down assays. U2OS cells were transfected with the indicated GST-p53
plasmids and then infected with Ad-GFP or Ad-Hzf. Twenty-four hours postinfection, the cells were lysed and subjected to GST pull-down. Western
blotting was then performed for p53 and FLAG epitope.
(D) Mutations in the DNA-binding domain of p53 affect the Hzf-p53 interaction. EJ cells containing nonfunctional p53 were transfected with the
indicated p53 plasmids and then infected with Ad-GFP or Ad-Hzf. Twenty-four hours postinfection, the cells were lysed and subjected to immuno-
precipitations using anti-p53 antibody. Western blotting was then performed for p53 and FLAG epitope.transfected into EJ cells followed by infection with control
Ad-GFP or Ad-Hzf. As shown in Figure 2C, Hzf bound to
GST-p53 (full length) but not to GST alone, supporting
our immunoprecipitation and yeast two-hybrid results.
The GST-p53 segment containing aa 100–300 specifically
bound to the Hzf protein, which represents the DNA-bind-
ing domain of p53 (Figure 2C). To study the Hzf-p53 inter-
action more closely, we determined whether Hzf could
bind to tumor-derived p53 DNA-binding domain mutants
including p53/175Pro, p53/175His, and p53/143Ala. It
was previously reported that p53/175His and p53/
143Ala have no DNA-binding ability while p53/175Pro is
capable of some DNA-binding activity but can trigger
only arrest and not apoptosis (Kern et al., 1991; Rowan
et al., 1996; Zhang et al., 1994). As shown in Figure 2D,
Hzf bound to WT p53 robustly, but reduced binding was
observed with p53/175Pro and p53/175His, and the bind-
ing of Hzf with p53/143Ala was severely repressed. Never-
theless, none of these p53 mutations was able to abolishthe Hzf-p53 interaction completely. This suggests that
p53-Hzf interaction involves several key residues in the
DNA-binding domain of p53 and that mutation in any
one of them weakens the binding but cannot fully abolish
it. Together, these results indicate that Hzf is induced by
p53 and directly binds to its DNA-binding domain.
Hzf Influences the Specificity of p53-Mediated
Transactivation
Since our results demonstrated that Hzf binds to p53 and
differentially modulates expression levels of the p53 tar-
gets p21 and Bax, we next determined whether this regu-
lation of p53 transactivation function by Hzf is a wide-
ranging phenomenon encompassing other proarrest and
proapoptotic p53 targets. To this end, we infected Hzf+/+
and Hzf/ MEFs with adenovirus expressing p53 (Ad-
p53) or treated the cells with etoposide and analyzed the
expression of p53 target genes including both proarrest
and proapoptotic targets. In the presence of Hzf, ectopicCell 130, 624–637, August 24, 2007 ª2007 Elsevier Inc. 627
p53 or etoposide treatment preferentially induced expres-
sion of the proarrest p53 targets p21 and 14-3-3s,
whereas in the absence of Hzf, the expression of the proa-
poptotic targets Bax, Perp, Puma, and Noxa was selec-
tively induced (Figures 3A and 3B). Induced levels of
Mdm2, a p53 target involved in p53 protein regulation
that does not specifically influence either arrest or apopto-
sis, were not affected by Hzf inactivation (Figures 3A and
3B). In addition, exogenous expression of Hzf in Hzf/
MEFs restored preferential induction of the cell-cycle ar-
rest targets p21 and 14-3-3s and lowered the levels of
Perp, Puma, Noxa, and Bax expression without any con-
comitant change in p53 induction of Mdm2 (Figure 3C).
To further evaluate the effect of Hzf on the transactiva-
tion function of p53, we measured DNA-binding activity of
p53 in response to DNA damage on the promoters of p53
targets including p21, 14-3-3s, Bax, Noxa, Perp, and
Mdm2 in Hzf+/+ and Hzf/ MEFs by ChIP assay. Hzf+/+
and Hzf/ MEFs were exposed to etoposide for 24 hr,
and ChIP assays were performed using control IgG or
p53 antibody for several p53 target genes. Upon DNA
damage treatment of Hzf+/+ MEFs, p53 predominantly
bound to the promoters of proarrest targets such as p21
and 14-3-3s, but DNA-binding activity of p53 on the pro-
moters of proapoptotic target genes such as Bax, Perp,
and Noxa was significantly lower (Figure 3D). In contrast,
in Hzf null MEFs, upon DNA damage, the DNA-binding
activity of p53 to the promoters of various proapoptotic
target genes, including Bax, Perp, and Noxa, was signifi-
cantly enhanced as compared to that of p21 and 14-3-
3s (Figure 3D). p53’s ability to bind to the Mdm2 and Hzf
promoters remained unchanged irrespective of Hzf status.
Quantitative ChIP assays by real-time PCR also confirmed
the above results with WT and Hzf/ MEFs (Figure S3).
These results strongly suggest that, upon Hzf binding to
p53, p53 is preferentially recruited to the promoters of
its cell-cycle-arrest-mediating target genes. To further
verify this, we performed ‘‘re-ChIP’’ experiments using
Hzf antibody. As shown in Figure 3E, Hzf was detected
at the promoters of p21, 14-3-3s, Hzf, and Mdm2, but
not at the promoters of Bax, Noxa, and Perp. Moreover,
quantitative ChIP assays by real-time PCR were carried
out with etoposide-treated p53+/+ and p53/ MEFs using
IgG control antibody and Hzf antibody (Figure S4), the re-
sults of which indicated that Hzf is found at the cell-cycle
arrest promoters only in the presence of p53. To further
determine the differential effects of Hzf binding on the
DNA-binding activities of p53 to its targets, an electropho-
retic mobility shift assay was carried out in etoposide-
treated Hzf+/+ and Hzf/ MEFs using oligonucleotides
specific for the p53 binding site in the p21 promoter (El-
Deiry et al., 1993), the Mdm2 promoter (Wu et al., 1993),
and the first intron of Bax (Thornborrow et al., 2002). As
shown in Figure 3F, the DNA-binding activity of p53 on
the p21 promoter was significantly increased in etopo-
side-treated WT MEFs, whereas there was no strong
DNA-binding activity of p53 on the first intron of Bax. In
the absence of Hzf, no significant binding activity of p53628 Cell 130, 624–637, August 24, 2007 ª2007 Elsevier Inc.was observed on the p21 promoter, but significantly
higher DNA-binding activities were seen on the first intron
of Bax (Figure 3G). The binding of p53 to the Mdm2 pro-
moter remained unchanged irrespective of Hzf status.
Taken together, these data demonstrate that Hzf prefer-
entially enhances the DNA-binding and transactivation
functions of p53 on cell-cycle arrest targets such as p21
and 14-3-3s.
Hzf Promotes the Cell-Cycle Arrest Function of
p53
We next examined the effects of Hzf on p53-mediated
cell-cycle arrest and apoptosis in Hzf+/+ and Hzf/
MEFs. In Hzf+/+ MEFs, the ectopic expression of p53 by
Ad-p53 infection induced prominent G1 arrest but little
apoptosis (Figure 4). In Hzf/ MEFs, the apoptotic func-
tion of p53 was significantly enhanced, as measured by
TUNEL assay, sub-G1 population, and DNA fragmenta-
tion (Figures 4A and 4B). To further verify whether Hzf de-
ficiency indeed modulates p53 functions under physiolog-
ical conditions, Hzf+/+ and Hzf/ MEFs were exposed to
etoposide, and TUNEL-positive apoptotic cells were then
measured. The loss of Hzf led to enhanced apoptosis sen-
sitivity to etoposide (Figure 4C, left panel). Re-expression
of Hzf in Hzf/ MEFs through Ad-Hzf infection reversed
this effect of Hzf deficiency and resulted in a decrease
in apoptosis induced by etoposide treatment or overex-
pression of p53, similar to that seen in etoposide-treated
or Ad-p53 infected Hzf+/+ MEFs (Figure 4C). This was due
to altered DNA-binding activity of p53 (Figure S5). These
results indicate that Hzf modulates the p53-mediated
stress response favoring cell-cycle arrest over apoptosis.
Prolonged p53 Expression/Activation or Extended
Exposure to Stress Results in Hzf Protein
Degradation Leading to Apoptosis
To examine whether levels of Hzf expression are corre-
lated with levels of genotoxic stress, we investigated the
kinetics of Hzf induction over extended periods during
stress response in U2OS cells. The results shown in
Figure 5A suggest that Hzf protein expression is induced
within 36 hr in response to etoposide treatment or ectopic
p53 expression; however, beyond 36 hr, Hzf protein levels
start declining and are markedly decreased at 72 hr. p21
expression also followed a pattern similar to that observed
with Hzf. In contrast, Bax protein levels rose very slowly up
to 36 hr but exhibited a sharp increase beyond that time
(Figure 5A).
We also immunoprecipitated p53 over the time course
of etoposide treatment to examine the amount of Hzf
bound to p53. We found that there was a sharp decline
in the amount of p53-bound Hzf beyond the 36 hr time
point to undetectable levels by 72 hr (Figure 5B). However,
Hzf mRNA levels remained steady throughout the time
course while mRNA levels of p21 and Bax were similar to
their protein levels (Figure 5C), suggesting that Hzf down-
regulation is due to the degradation of the Hzf protein.
Figure 3. p53 Bound to Hzf Is Preferentially Recruited to the p21 and 14-3-3s Promoters
(A and B) Loss of Hzf enhances expression of proapoptotic targets of p53 but suppresses expression of p21 and 14-3-3s. Hzf+/+ and Hzf/ MEFs
were infected with Ad-GFP or Ad-p53 (A) or treated with ETO (40 mM) (B). Twenty-four hours later, western blot analysis was performed for the
indicated proteins.
(C) Re-expression of Hzf restores preferential induction of p21 and 14-3-3s and represses proapoptotic targets in response to p53.Hzf/ MEFs were
infected with Ad-GFP or Ad-Hzf 6 hr prior to infection with Ad-GFP or Ad-p53. Twenty-four hours postinfection, western blots were performed for the
indicated proteins.
(D) Multiple ChIP analysis on the promoters of p53 targets. Wild-type and Hzf/ MEFs were treated with ETO (40 mM). Twenty-four hours post drug
treatment, ChIP was carried out using control mouse IgG or anti-p53 antibody, and PCR was performed for the indicated promoters.
(E) Part of the chromatin immunoprecipitated with p53 antibody was again subjected to ChIP using control rabbit IgG or Hzf antibody. Input represents
2% of total chromatin from untreated Hzf+/+ MEFs used for immunoprecipitation.
(F and G) EMSA showing the DNA-binding activity of p53 to oligonucleotides containing the p53 binding site in the p21 promoter, the first intron ofBax,
and the Mdm2 promoter in wild-type MEFs (F) and Hzf null MEFs (G). Wild-type and Hzf/ MEFs were treated with ETO (40 mM). Twenty-four hours
post drug treatment, nuclear extracts were prepared, and EMSA was performed as described in Supplemental Experimental Procedures. The arrows
indicate the position of the p53-DNA complex (lower arrow) and the supershifted complex containing anti-p53 antibody (pAb421) (upper arrow).Cell 130, 624–637, August 24, 2007 ª2007 Elsevier Inc. 629
Figure 4. Hzf Promotes the Cell-Cycle Arrest Function of p53
(A) Hzf+/+ and Hzf/ MEFs were infected with Ad-GFP or Ad-p53. Twenty-four hours postinfection, FACS analysis was performed.
(B) Hzf+/+ and Hzf/ MEFs were treated as in (A), and TUNEL staining and DNA fragmentation assays were performed. Error bars are means ± SD of
three independent experiments.
(C) Re-expression of Hzf decreases apoptosis in response to ETO or p53 overexpression in Hzf/ MEFs. Wild-type MEFs and Hzf/ MEFs were
treated with ETO (40 mM). In cases where the cells were infected with Ad-GFP or Ad-Hzf prior to drug treatment, there was a difference of 6 hr between
viral infection and drug treatment. Twenty-four hours post drug treatment, the cells were subjected to TUNEL assay. Error bars are means ± SD of
three independent experiments.To determine the implications of these differential re-
sponses in Hzf protein levels in response to genotoxic
stress or ectopic p53 induction, we next tested the cell-
cycle profile under these conditions by flow cytometry.
Ad-p53 overexpression induced a pronounced arrest in
the G1 phase of the cell cycle at 24–36 hr (Figure 5D), after
which there was a marked increase in the apoptotic pop-
ulation. TUNEL staining confirmed these results (Fig-
ure 5E). These results indicate that extended exposure
to stress and the induction of a p53-mediated apoptotic
response are correlated with a reduction of Hzf, suggest-
ing that Hzf may play a role in controlling the switch in the
p53-dependent stress response.
Since the ubiquitin-mediated proteasome degradation
pathway is a frequently engaged mechanism for protein
downregulation, we investigated the potential role of the630 Cell 130, 624–637, August 24, 2007 ª2007 Elsevier Inc.proteasome in stress-induced Hzf protein degradation
in cells undergoing p53-dependent apoptotic response.
We treated U2OS cells with etoposide for 0, 36, and 72
hr. At 10 hr prior to the end of the 72 hr period, the cells
were treated with the proteasome inhibitor MG132. Loss
of Hzf triggered by genotoxic stress at the 72 hr time point
was significantly attenuated by MG132, resulting in ele-
vated p21 levels (Figure 5F). However, Bax levels were
diminished at 72 hr in the MG132-treated U2OS cells sim-
ilarly to those at 36 hr (Figure 5F). Furthermore, protea-
some inhibitor treatment elevated the levels of p21
mRNA but decreased Bax mRNA (Figure 5G), supporting
the hypothesis that the preferential DNA-binding activities
of p53 to the p21 promoter result from stabilization of Hzf
protein. This was confirmed by ChIP as well as quantita-
tive ChIP assays by real-time PCR (Figure 5H; Figure S6A).
Figure 5. Sustained p53 Activation Promotes Ubiquitination and Degradation of Hzf
(A) Prolonged p53 activation induces Hzf protein downregulation. U2OS cells were exposed to ETO (40 mM) or infected with Ad-GFP or Ad-p53 for the
indicated periods. The cells were lysed, and western blots were performed for the indicated proteins.
(B) U2OS cells exposed to ETO (40 mM) for the indicated periods were immunoprecipitated with anti-p53 antibody, and the precipitates were immu-
noblotted with anti-Hzf antibody.
(C) Hzf mRNA levels remain steady in response to ETO treatment. U2OS cells were exposed to ETO (40 mM) for the indicated periods, and northern
blots were performed as indicated.
(D) U2OS cells were infected with Ad-GFP or Ad-p53 for the indicated periods, and FACS analysis was performed.
(E) U2OS cells were treated as in (A), and TUNEL assays were performed for the indicated periods. Error bars are means ± SD of three independent
experiments.
(F–H) Proteasome-dependent Hzf degradation. U2OS cells were treated for 36 and 72 hr with ETO (40 mM), and MG132 (10 mM) was added during the
last 10 hr prior to the end of the 72 hr period. The cells were then harvested, and western blotting (F), northern blotting (G), or ChIP (H) was performed
with the indicated antibodies. Input represents 2% of total chromatin from untreated U2OS cells used for immunoprecipitation.
(I) Genotoxic stress-induced ubiquitination of Hzf. U2OS cells were treated with ETO (40 mM) for 36 and 72 hr, and with MG132 for the last 10 hr. Cell
extracts were immunoprecipitated with anti-Hzf antibody and immunoblotted with anti-ubiquitin antibody.Cell 130, 624–637, August 24, 2007 ª2007 Elsevier Inc. 631
We next determined whether prolonged stress in cells trig-
gers the polyubiquitination of Hzf prior to Hzf degradation.
Treatment of U2OS cells with etoposide in the presence of
MG132 revealed that endogenous Hzf undergoes exten-
sive ubiquitination after prolonged exposure (72 hr) to
genotoxic stress, while no such ubiquitinated forms
were observed at 36 hr of treatment (Figure 5I). Moreover,
MG132-mediated stabilization of Hzf indeed prevented
the p53-mediated apoptosis upon prolonged exposure
to genotoxic stress (Figures S6B and S6C). Thus, the
appearance of ubiquitinated forms of Hzf in cells treated
with MG132 supports the idea that the Hzf protein is tar-
geted for degradation following prolonged exposure to
genotoxic stress due to activation of a ubiquitination-
proteasome pathway resulting in initiation of the apoptotic
process.
Hzf/ Mice Exhibit Increased Sensitivity
to g Irradiation
While mice lacking Hzf seemed to be relatively phenotypi-
callynormal, initial characterization suggested a role for Hzf
in megakaryopoiesis and hemostasis (Kimura et al., 2002).
To further study the role of Hzf in genotoxic stress response
in vivo, we investigated the functional consequences of Hzf
deficiency in Hzf null mice exposed to g irradiation. Hzf/
mice and WT littermates (14 weeks old) were exposed to 5
Gy total-body g irradiation. 6.5 hr after treatment, three
mice from each group were evaluated by examining sensi-
tivity to cell death using TUNEL staining and histopatholog-
ical analysis of target organs including skin, spleen, small
intestine, and prostate. As shown in Figures 6A and 6B,
skin and prostate from irradiated Hzf/ mice showed in-
creased sensitivity to DNA damage induced byg irradiation
as measured by TUNEL staining. However, the extent of
apoptosis in WT prostate was less than that in skin and
was associated with increased expression of Hzf in pros-
tate as compared to skin (Figure 6C). TUNEL staining and
immunostaining for Hzf was also carried out in ionizing ra-
diation (IR)-sensitive tissues like spleen and small intestinal
epithelium, where we found extensive apoptosis and low
levels of Hzf expression upon g irradiation (Figure S7). In
spleen, no difference was observed in the levels of apopto-
sis betweenHzf+/+ andHzf/ samples in response to IR; in
contrast, in the small intestine, we observed slightly higher
levels of apoptosis in Hzf/ samples. Thus, our results
demonstrate an inverse correlation between sensitivity to
g irradiation and levels of Hzf expression.
We also performed immunostaining for the p53 targets
p21 and Bax in the same sections of skin and prostate
from WT and Hzf/ mice. In response to g irradiation,
the level of Bax expression was increased in Hzf/ skin
compared to skin from WT mice, while p21 levels were
reduced in g-irradiated Hzf/ skin samples (Figure 7A).
Similar results were obtained in prostate tissue from irradi-
ated Hzf/ mice (Figure 7B). In concurrence with TUNEL
staining, Bax staining inHzf/ prostate was also less pro-
nounced as compared to skin, while the pattern of p21
staining was reversed. These results support a role for632 Cell 130, 624–637, August 24, 2007 ª2007 Elsevier Inc.Hzf downstream of p53 in the p53-dependent DNA dam-
age response, acting as a critical switch that prevents ap-
optosis by repressing transactivation of proapoptotic p53
targets both in vitro and in vivo. Thus, the results from the
mouse model suggest that, under in vivo conditions, Hzf
modulates the p53-mediated stress response but that
there is an element of tissue specificity in this regulation
due to varying degrees of Hzf expression in different tis-
sues upon g irradiation.
DISCUSSION
It is widely accepted that the p53 tumor suppressor re-
stricts the proliferation of cells exposed to genotoxic
stress by inducing growth arrest or by triggering cell death
(Vousden and Lu, 2002). This process depends mainly on
the expression of genes that regulate cell-cycle arrest
and/or apoptosis. A critical unresolved issue about the
DNA damage response is how the resulting upregulation
of the p53 tumor suppressor can lead either to cell-cycle
arrest and DNA repair or to apoptosis. Here we present
evidence that Hzf plays a critical role in p53-mediated
transcription and functions as a key player in controlling
a cellular regulatory switch that dictates the cellular deci-
sion toward cell-cycle arrest in response to stress. The ex-
istence of an autoregulatory feedback loop involving p53
and its target proteins such as Mdm2, Pirh2, and Cop1
is well established (Dornan et al., 2004; Leng et al.,
2003; Wu et al., 1993). These proteins are known to
have ubiquitin ligase activity and can target p53 for ubiq-
uitination and degradation to maintain low basal levels of
the p53 protein. Unlike these p53 target proteins, Hzf is
a zinc-finger domain protein, and its binding to p53 does
not seem to regulate p53 stability in response to stress. In-
stead, induction of Hzf and its binding to p53 selectively
influence the specificity of p53-mediated transcription, re-
sulting in preferential transactivation of downstream cell-
cycle arrest target genes such as p21 and 14-3-3s.
It has been previously shown that Hzf is a direct p53
transcriptional target in NIH 3T3 cells (Sugimoto et al.,
2006). Promoter analyses revealed that p53 could bind di-
rectly to the p53-responsive element in the first intron of
the Hzf gene. Moreover, Hzf was found to have a role in
cell-cycle checkpoint control, specifically at the G2/M
checkpoint. Strikingly, knockdown of Hzf expression pro-
moted p21 ubiquitination and degradation, the mecha-
nism of which was not elucidated. We independently iden-
tified Hzf as a p53 target gene in human cells, and our
promoter analysis strongly suggests that, unlike mouse
Hzf, the p53-responsive element in human Hzf is located
at the 1044 base pair of the promoter region (Figure S1).
Our results show further that Hzf binds to p53, resulting in
preferential transactivation of proarrest p53 target genes.
Thus, upon genotoxic stress, abrogation of Hzf expression
results in preferential transactivation of proapoptotic p53
target genes such as Bax, Perp, Puma, and Noxa over
its proarrest targets such as p21 and 14-3-3s. Hence,
our results argue that downregulation of p21 and other
Figure 6. Increased Apoptosis after Radiation-Induced DNA Damage in Skin and Prostate of Hzf-Deficient Mice versus Wild-Type
Mice
(A) Representative TUNEL staining of skin from Hzf/ mice and wild-type (WT) littermates, analyzed 6.5 hr after the mice received 5 Gy total-body
irradiation. Respective hematoxylin and eosin (H&E) sections are shown at left. Percentages of TUNEL-positive cells calculated from three indepen-
dent experiments are shown at right. Error bars are means ± SD of three independent experiments.
(B) Representative TUNEL staining of prostate tissue from the same IR-treated Hzf/ mice and wild-type littermates as in (A). Respective H&E
sections are shown at left. Percentages of TUNEL-positive cells calculated from three independent experiments are shown at right. Error bars are
means ± SD of three independent experiments.
(C) Immunostaining for Hzf in skin and prostate from the same IR-treated Hzf/ mice and wild-type littermates as in (A).proarrest p53 targets in the absence of Hzf is transcrip-
tional in nature.
Our results also indicate that the level of Hzf protein is
inversely correlated with the extent of genotoxic stress.
Prolonged p53 activation/expression or extended expo-
sure to stress induced Hzf protein degradation through ac-
tivation of a ubiquitination-proteasome pathway whose
consequences are induction of proapoptotic p53 targets
such as Bax, Puma, Noxa, and Perp. Thus, we propose
a model (Figure 7C) wherein p53 activates Hzf, whichthen binds to p53 in an autoregulatory feedback loop.
Hzf-bound p53 is specifically recruited to cell-cycle arrest
gene promoters, resulting in growth arrest. Prolonged p53
expression is associated with Hzf degradation, which then
allows p53 activation of proapoptotic targets, resulting in
apoptosis. However, if cells lack the mechanism for Hzf
degradation, prolonged p53 expression leads to senes-
cence, and shRNA-mediated inhibition of Hzf expression
makes the cells highly apoptotic (Figure S8). Therefore,
our results provide a novel mechanism for modulation ofCell 130, 624–637, August 24, 2007 ª2007 Elsevier Inc. 633
Figure 7. Loss of Hzf Enhances Expression of Bax, but Levels of p21 Expression Are Reduced in Skin and Prostate
(A) Immunostaining for p21 and Bax proteins in skin from the same IR-treated Hzf/ mice and wild-type littermates as in Figure 6A.
(B) Immunostaining for p21 and Bax proteins in prostate tissue from the same IR-treated Hzf/ mice and wild-type littermates as in Figure 6B.
(C) Model for p53-dependent cell fate control through the p53/Hzf/p53/Hzf autoregulatory feedback loop. p53 activation by DNA damage induces
Hzf, which binds to p53. This directs p53 preferentially to cell-cycle arrest gene promoters, resulting in growth arrest. Upon extended or irreparable
stress, Hzf ubiquitination/degradation prevents this from occurring, thus allowing p53 to activate proapoptotic targets and resulting in apoptosis. The
ubiquitin ligase and the proteins that facilitate the interaction between Hzf and the ubiquitin ligase are currently unknown.634 Cell 130, 624–637, August 24, 2007 ª2007 Elsevier Inc.
a p53-dependent DNA damage response. It will be of inter-
est to determine the expression pattern of p53-regulated
genes by microarray analysis in the absence or presence
of Hzf as well as the specific interacting partner (or
partners) that mediates Hzf ubiquitination/degradation.
Recently, it was shown that Tip60-dependent acetylation
of p53 at lysine 120 modulates the decision between cell-
cycle arrest and apoptosis, leading to enhanced p53-
dependent apoptotic response (Sykes et al., 2006; Tang
et al., 2006). Thus, it will be interesting to determine
whether the acetylation of K120 within the DNA-binding
domain of p53 affects Hzf-mediated preferential transacti-
vation of proarrest p53 target genes. While the role of
Mdm2 in p53 regulation is well established, we found that
there is no role for Mdm2 in Hzf degradation (Figure S9).
Another question remains as to whether cells that have
a deficiency of one or more proarrest or proapoptotic p53
targets can affect the Hzf-mediated cell fate decision
upon genotoxic stress. In HCT116 and HCT116 p21/
cells, genotoxic stress results in cell-cycle arrest in both
cell lines, with p21/ cells showing a higher extent of
G2/M arrest. When Hzf is also knocked down under
such conditions, both cell lines show much-increased ap-
optosis levels with marginal differences between them
(Figure S10). Thus, Hzf likely plays a key role in sustaining
p53-mediated cell-cycle arrest through other proarrest
p53 target genes such as 14-3-3s in addition to p21. It
is well established that HCT116 Bax/ cells are resistant
to apoptosis upon DNA damage (Zhang et al., 2000).
When Hzf was depleted in parental HCT116 and
HCT116 Bax/ cells, there was a significant induction
of apoptosis in both cell types following DNA damage;
however, the extent of apoptosis was higher in wild-type
cells (data not shown). Thus, Hzf appears to influence
cell fate following genotoxic stress through modulation
of p53-mediated transactivation of multiple proarrest
and proapoptotic genes.
TargetedHzfdisruption in the mouse germline has no re-
ported effects on cell-cycle dynamics, but general growth
retardation and internal hemorrhaging in the brains of
Hzf/ mice have been observed (Kimura et al., 2002).
While mice lacking Hzf seemed to be otherwise normal,
the initial characterization of Hzf null mice suggested a
role for Hzf in megakaryopoiesis and hemostasis. Based
on our in vitro characterization of the role of Hzf in p53-
dependent stress response, we carried out an analysis of
Hzf function in response to irradiation under in vivo condi-
tions usingHzf knockout mice. We observed that exposure
to IR results in increased cell death inHzf/ mice as com-
pared to wild-type littermates, especially in the epidermis
and prostate epithelium. However, comparison of the
extent of apoptosis between the different tissues of g-irra-
diated Hzf/ mice revealed significant differences, indic-
ative of some tissue specificity with respect to Hzf function
due to varying degree of Hzf expression in different tissues
upon g irradiation. While our preliminary investigations re-
veal some evidence for epithelial hyperplasia in organs like
lung, mammary gland, etc. of Hzf/ mice, further studieswill be needed to elucidate the role of Hzf in tumor suscep-
tibility in mice and its implications for human cancer.
The findings presented here establish that Hzf functions
downstream of p53 in the DNA damage response and
acts as a critical switch favoring cell-cycle arrest over ap-
optosis. Hzf appears to govern this key event by promoting
preferential transactivation of proarrest p53 targets both in
vitro and in vivo. Thus, Hzf is both a p53 target and an im-
portant modulator of p53 functions, adding a new layer of
complexity to the mechanisms by which p53 determines
cell fate decisions in response to cellular stresses.
EXPERIMENTAL PROCEDURES
Cell Lines and Culture Conditions
U2OS, LNCaP, Saos2, HCT116, HCT116 p53/ (Bunz et al., 1998),
HCT116 p21/ (Waldman et al., 1996), and HCT116 Bax/ (Zhang
et al., 2000) cells were cultured in DMEM containing fetal bovine serum
(FBS) (Invitrogen), 100 U/ml penicillin, and 100 mg/ml streptomycin at
37C. Hzf+/+ and Hzf/ early-passage MEFs (Kimura et al., 2002)
were also maintained in DMEM containing 10% FBS. For drug treat-
ment, cells were grown to 50% confluency prior to exposure to the
DNA-damaging agents for the indicated time. Adenoviruses express-
ing Hzf or GFP were generated, amplified, and titrated as previously
reported (Ongusaha et al., 2003). Cells were grown to 50%–70%
confluency and infected with recombinant adenovirus at a multiplicity
of infection of 10–20 for the indicated time. GFP-expressing adenovi-
rus (Ad-GFP) was used as a control.
GST Pull-down Assay and Yeast Two-Hybrid Assay
Cells were lysed in lysis buffer (20 mM Tris-HCl [pH 7.4], 5 mM EDTA,
10 mM Na4P2O7, 100 mM NaF, 2 mM Na3VO4, 1% NP-40, 1 mM phe-
nylmethylsulfonyl fluoride [PMSF], 13 protease inhibitor cocktail
[Roche]). Five hundred microgram cell extracts pretreated with MNase
as described (Groisman et al., 2003) were subjected to GST pull-down
following the manufacturer’s protocol (Amersham). Yeast two-hybrid
assay was performed following the manufacturer’s protocol (Clon-
tech). Briefly, Hzf cloned in the pGADT7 vector was transformed into
yeast strain Y187, mated with yeast strain AH109 carrying the
pGBKT7-p53 plasmid, and then plated on SD/Trp/Leu and SD/
Trp/Leu/Ade/His plates. Representative colonies for the posi-
tive control, negative controls, and the test interaction were then
streaked onto a SD/Trp/Leu/Ade/His/X-a-Gal plate.
Apoptosis and Flow Cytometry
Apoptosis was detected using the Cell Death Detection ELISA kit
(Roche) and TUNEL assay (Roche). For Cell Death Detection ELISA,
cells were lysed, and the amount of nucleosomes in the cytoplasmic
fraction of the cell lysates was measured using anti-histone antibody
and anti-DNA antibody linked to peroxidase in a sandwich ELISA-
based protocol. For calculating relative nucleosome content, the ab-
sorbance of all of the samples was normalized with respect to that of
untreated/untransfected cells. Error bars are means ± SD of three in-
dependent experiments with triplicate samples. For TUNEL assay,
cells were fixed with paraformaldehyde, stained by TUNEL reaction
using TMR red-conjugated nucleotides, and counterstained with
DAPI. For each sample, five random fields were counted, and error
bars are means ± SD of three such independent experiments. Cell-
cycle analysis using flow cytometry was carried out as described
previously (Han et al., 2002).
shRNA
Vectors expressing shRNA against Hzf (50-ATCCGCTTCAATTCTCA
GA-30) and the scrambled sequence (50-GAGCCCTATTTCACAACTT-
30) were generated using the pBabe-U6-shRNA plasmid. Cells wereCell 130, 624–637, August 24, 2007 ª2007 Elsevier Inc. 635
transfected with Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol.
Total-Body Irradiation and Immunohistochemistry
Fourteen-week-old Hzf/ mice and age- and sex-matched wild-type
littermates were subject to 5 Gy of total-body irradiation with a 137Cs g
source at a rate of 0.6 Gy/min. All animal protocols were approved by
the Massachusetts General Hospital Institutional Animal Care and Use
Committee. 6.5 hr later, the animals were euthanized. Tissues were
harvested, fixed in formalin, washed with PBS, and embedded in par-
affin for sectioning. Immunohistochemical analyses of the tissues were
carried out by fluorescence microscopy. Briefly, 5 mm paraffin sections
were dewaxed and immunostained with Bax (Santa Cruz) or p21
(Calbiochem) antibody followed by counterstaining with TO-PRO-3
(Invitrogen). TUNEL staining of dewaxed sections was carried out as
described above.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, and ten figures and can be found with
this article online at http://www.cell.com/cgi/content/full/130/4/624/
DC1/.
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